Diagenode

ZBTB11 dysfunction: spectrum of brain abnormalities, biochemicalsignature and cellular consequences.


Sumathipala D. et al

Bi-allelic pathogenic variants in ZBTB11 have been associated with Intellectual Developmental Disorder, autosomal recessive 69 (MRT69; OMIM 618383). We report five patients from three families with novel, bi-allelic variants in ZBTB11. We expand the clinical phenotype of MRT69, documenting varied severity of atrophy affecting different brain regions. We also describe combined malonic and methylmalonic aciduria (CMAMMA) as a biochemical manifestation. Since ZBTB11 encodes for a transcriptional regulator, we performed Chromatin immunoprecipitation (ChIP)-sequencing targeting ZBTB11 in fibroblasts from patients and controls. ChIP-seq reveals binding of wild-type ZBTB11 to promoters in 238 genes, among which genes encoding proteins involved in mitochondrial functions and RNA processing are over-represented. Mutated ZBTB11 shows reduced binding to 61 of the targeted genes, indicating that the variants act as loss of function. The majority of these genes are related to mitochondrial functions. Transcriptome analysis of the patient fibroblasts reveals dysregulation of mitochondrial functions. In addition, we uncover that reduced binding of the mutated ZBTB11 to ACSF3 leads to decreased ACSF3 transcript level, explaining CMAMMA. Collectively, these results expand the clinical spectrum of ZBTB11-related neurological disease and give insight into the pathophysiology in which the dysfunctional ZBTB11 affect mitochondrial functions and RNA processing contributing to the neurological and biochemical phenotypes.

Tags
Bioruptor
Chromatin Shearing

Share this article

Published
February, 2022

Source

Products used in this publication

  • chip kit icon
    C01020013
    Chromatin EasyShear Kit - Low SDS

活动

  • APHL 2024
    Milwaukee, Wisconsin, USA
    May 6-May 9, 2024
 查看所有活动

新闻

 查看所有新闻


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics